Pharmaceutical

Health Canada approves Servier’s VORANIGO for IDH-mutant glioma

Servier Canada has announced Health Canada's approval of VORANIGO for Grade 2 IDH-mutant glioma in adults and paediatric patients.

Oct 24, 2024 - 04:00
Health Canada approves Servier’s VORANIGO for IDH-mutant glioma
Servier Canada has announced Health Canada's approval of VORANIGO for Grade 2 IDH-mutant glioma in adults and paediatric patients.
Read the original article

Tags:

Previous Article

AAO 2024: NMA reveals Vabysmo’s superior CST improvement over Eylea HD

Next Article

A slow start for self-amplifying mRNA vaccines

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

How orphan designated drugs private equity performed in the pharmaceutical industry in Q2 2023

How orphan designated drugs private equity performed in...

Jul 21, 2023

STAT+: Scientists use ‘mini-brains’ to study microglia, the brain’s cleanup crew and key players in neurological disease

STAT+: Scientists use ‘mini-brains’ to study microglia,...

May 11, 2023

After AdCom rejection, FDA rebuffs Novo Nordisk’s once-weekly insulin

After AdCom rejection, FDA rebuffs Novo Nordisk’s once-...

Jul 12, 2024